title: Effect of clentiazem (TA-3090) with posttreatment on neurologic and histologic disorders of stroke-prone spontaneously hypertensive rats with history of stroke.
abstract: After stroke-prone spontaneously hypertensive rats (SHRSP) received a salt-loaded diet to accelerate onset of stroke, the therapeutic effect of clentiazem, a benzothiazepine Ca antagonist, on neurologic and histologic disorders was examined. Treatment with clentiazem (3, 15, and 30 mg/kg) orally twice daily (b.i.d.) for 28 days after the occurrence of stroke reduced neurologic symptoms and histologic changes of brain and kidney in a dose-dependent manner. Acute treatment with clentiazem (15 mg/kg, b.i.d.) administered immediately after stroke for 1 week not only almost completely abolished neurologic symptoms during treatment, but partially improved them even after treatment. Subacute treatment with clentiazem starting 10 days after stroke and continuing for 18 days also suppressed the neurologic signs. Both acute and subacute treatment improved cerebral histology. These results suggest that clentiazem treatment in the acute and subacute phases of stroke is beneficial.
authors.affiliation: Pharmacological Research Laboratory, Tanabe Seiyaku Co., Ltd., Saitama, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Kikkawa
authors.forename: S
authors.initials: S
authors.lastname: Murata
authors.forename: H
authors.initials: H
authors.lastname: Kurosawa
authors.forename: W
authors.initials: W
authors.lastname: Toriumi
authors.forename: H
authors.initials: H
authors.lastname: Iwasaki
authors.forename: T
authors.initials: T
authors.lastname: Nagao
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D001921:Brain / Q000187:drug effects / Q000473:pathology*; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000473:pathology; D004110:Diltiazem / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D006339:Heart Rate / Q000187:drug effects; D006973:Hypertension / Q000188:drug therapy*; D007668:Kidney / Q000187:drug effects / Q000473:pathology*; D009420:Nervous System / Q000187:drug effects; D051381:Rats; D011918:Rats, Inbred SHR; D012982:Sodium, Dietary
chemical_list: D000959:Antihypertensive Agents; D012982:Sodium, Dietary; C056595:clentiazem; D004110:Diltiazem